Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer

Don S Dizon, Lars Damstrup, Neil J Finkler, Ulrik Lassen, Paul Celano, Ros Glasspool, Elizabeth Crowley, Henri S Lichenstein, Poul Knoblach, Richard T Penson

    77 Citationer (Scopus)

    Abstract

    Preclinical data show that belinostat (Bel) is synergistic with carboplatin and paclitaxel in ovarian cancer. To further evaluate the clinical activity of belinostat, carboplatin, and paclitaxel (BelCaP), a phase 1b/2 study was performed, with an exploratory phase 2 expansion planned specifically for women with recurrent epithelial ovarian cancer (EOC).
    OriginalsprogEngelsk
    TidsskriftInternational Journal of Gynecological Cancer
    Vol/bind22
    Udgave nummer6
    Sider (fra-til)979-86
    Antal sider8
    ISSN1048-891X
    DOI
    StatusUdgivet - 2012

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater